Marine Organism-Derived Protein Drug Candidate against MRSA under Development
Eden Biodesign and Aquapharm BioDiscovery join forces.!--h2>
Eden Biodesign will develop Aquapharm BioDiscovery’s AQP001, a natural marine product that it identified as a potential antibacterial against bacteria-resistant antibiotics, including MRSA. “To our knowledge, this is the first instance of a protein pharmaceutical derived from a marine organism entering commercial development,” comments Crawford Brown, CEO of Eden Biodesign.
Eden Biodesign will assist Aquapharm BioDiscovery in large-scale, standardized production of AQP001 to continue testing and clinical development of this therapeutic. The National Biomanufacturing Centre, where the development work will be carried out, awarded Aquapharm Biodiscovery a grant.